LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary
This week, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with Juliette Saly from ausbiz to discuss the Company’s progress in the advancement of rapid treatment for Erectile Dysfunction (ED), SPONTAN®, including the commencement of recruitment for its pivotal bioequivalence study. Take a look:
LTR Pharma is pleased to announce the commencement of patient dosing in the Company’s pivotal bioequivalence clinical study of SPONTAN® nasal spray. The clinical study will assess the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment for ED. This first-in-kind nasal spray will be compared to
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711